Patent Acquisitions
AM Biotech’s patented technology has been granted patents in the Republic of Korea.
●「EXOSOMEAND PREPARATION PROCESS AND USE THEREOF」（Patent Number：10-2798032）

Patent Acquisitions
AM Biotech’s patented technology has been granted patents in the US. And it is currently undergoing patent examination in other countries.
● ” EXOSOMEAND PREPARATION PROCESS AND USE THEREOF ” was granted a US patent (Certificate Number: US012186429B2)

AM Biotech Bio-Pulsed Exosomes entered the top 5 finalists pioneering innovation “Estée Lauder (NIV) BRKTHRU VOICES Prize”

Patent Acquisitions
AM Biotech’s patented technology has been granted patents in Taiwan ,China and Japan. And it is currently undergoing patent examination in other countries.
● “Method for Producing Exosomes and the Exosomes Produced Thereby and Their Applications” was granted a Taiwan patent (Certificate Number: I828062)
● “An Induced Enhancement Preparation Process and Application of Avian Mesenchymal Stem Cell Exosomes” was granted a China patent (Patent Number: ZL 2021 1 0794777.X)

Academic Journal Publication
The efficacy and validation methods of Bio-Pulsed Exosomes have been published in the international journal “International Journal of Molecular Sciences” (Impact Factor: 6.2).

New Drug and Medical Material Development 
Initiated academic research collaborations on premature ovarian failure, degenerative arthritis, macular degeneration, special trauma, post-cancer treatment repair, periodontitis, alveolar bone repair, ischemic stroke, and hearing loss treatment.

Using NGS (Next Generation Sequencing) and QPCR (Quantitative Polymerase Chain Reaction) to establish a guidance model for biochemical pulse exosomes 
✓ Capable of producing exosomes with varied gene expressions and therapeutic effects tailored to diverse treatment needs.
✓ Both liquid and lyophilized exosomes can be preserved at room temperature.

Acquired INCI
ExoGiov obtained the International Cosmetic Ingredient Nomenclature (INCI) name: Chicken Embryonic Mesenchymal Cell-Derived Extracellular Vesicles.

Laboratory Establishment
Established a laboratory compliant with GMP standards, continuously developing exosome-related technologies. 

Guiding miRNA Gene Expression and Clinical Efficacy in Exosomes
Effectively enhanced exosome efficacy: such as nerve repair, hair follicle cells, osteoblasts, chondrocytes, collagen, elastin proliferation efficiency, and anti inflammatory effects, among others. 

AM Biotech Established 
Industrialization initiated in Taiwan, developing exosomes and their derivative products.

Initiation of Stem Cell Enhancement of Exosome Secretion
1. Lyophilized Powder Room Temperature Preservation Production Technology
2. Enhancement of Exosome Vesicle Particle Count, Vesicular MiRNA, and Protein Concentration

Research and Development Incubation
AM Biotech originated as IRH Technology Co., Ltd., established in 2015, and began investing in exosome research and development incubation in 2017.